Atalanta Therapeutics

Executive Summary

Atalanta Therapeutics is a preclinical biotechnology company pioneering RNA interference (RNAi) therapeutics for neurodegenerative diseases, with a focus on genetically defined central nervous system disorders such as Huntington's disease and ALS. Founded in 2020 and headquartered in Boston, the company has raised $97 million to advance its proprietary delivery platforms that enable targeted gene silencing in the CNS. By leveraging RNAi technology, Atalanta aims to address the root cause of these devastating diseases, offering potential disease-modifying treatments. The company's lead programs are in preclinical development, with plans to move toward clinical trials in the near term. Atalanta's approach holds promise for patients with high unmet medical need, though the early-stage nature and technical challenges of CNS delivery represent significant risks.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Program in Huntington's Disease70% success
• Q2 2026Preclinical Data Presentation for ALS Program80% success
• Q3 2026Series B or Additional Funding Round60% success